NCT04647032

Brief Summary

The overall goal of this project is to improve cognitive control abilities in adults with mild cognitive impairment (MCI) through a form of non-invasive brain stimulation, transcranial alternating current stimulation (tACS).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 10, 2020

Completed
20 days until next milestone

First Posted

Study publicly available on registry

November 30, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

January 11, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2022

Completed
12 months until next milestone

Results Posted

Study results publicly available

May 11, 2023

Completed
Last Updated

May 11, 2023

Status Verified

April 1, 2023

Enrollment Period

12 months

First QC Date

November 10, 2020

Results QC Date

December 28, 2022

Last Update Submit

April 19, 2023

Conditions

Outcome Measures

Primary Outcomes (6)

  • Divided Attention Performance

    Divided attention was assessed as the difficulty level achieved during perceptual discrimination performance while participants were engaged in the Akili AKL-T01 task. Higher is better.

    Post-tACS (1-day follow-up), approximately 1 week after baseline

  • Divided Attention Performance

    Divided attention was assessed as the difficulty level achieved during perceptual discrimination performance while participants were engaged in the Akili AKL-T01 task. Higher is better.

    Post-tACS (1-month follow-up), approximately 1 month after baseline

  • Sustained Attention Performance

    Sustained attention was assessed via response times to visual targets during the continuous performance task. Lower is better.

    Post-tACS (1-day follow-up), approximately 1 week after baseline

  • Sustained Attention Performance

    Sustained attention was assessed via response times to visual targets during the continuous performance task. Lower is better.

    Post-tACS (1-month follow-up), approximately 1 month after baseline

  • Working Memory Performance

    Working memory was assessed as the average maximum number correct from the ACE-X span tasks - memory for order of illuminated squares.

    Post-tACS (1-day follow-up), approximately 1 week after baseline

  • Working Memory Performance

    Working memory was assessed as the average maximum number correct from the ACE-X span tasks - memory for order of illuminated squares

    Post-tACS (1-month follow-up), approximately 1 month after baseline

Secondary Outcomes (2)

  • Instrumental Activities of Daily Living (IADL)

    Post-tACS (1-day follow-up), approximately 1 week after baseline

  • Instrumental Activities of Daily Living (IADL)

    Post-tACS (1-month follow-up), approximately 1 month after baseline

Study Arms (2)

Theta Stimulation Group

EXPERIMENTAL

This group will receive 6 Hz (theta) stimulation

Device: Transcranial alternating current stimulation

Delta Stimulation Group

ACTIVE COMPARATOR

This group will receive 1 Hz (delta) stimulation

Device: Transcranial alternating current stimulation

Interventions

Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4

Delta Stimulation GroupTheta Stimulation Group

Eligibility Criteria

Age60 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • English speaking
  • Grade 12 or more education
  • Normal or corrected to normal vision and hearing
  • Ability to complete cognitive tasks
  • Ability to cooperate and comply with all study procedures
  • Ability to tolerate tACS
  • Montreal Cognitive Assessment score: 17-28
  • z-score on immediate memory, delayed memory, fluency, processing speed, or task switch
  • Self-reported memory complaint

You may not qualify if:

  • Neurological or psychiatric disorders other than mild cognitive impairment
  • Receiving investigational medications or have participated in a trial with investigational medications within last 30 days
  • Family history of epilepsy
  • Implanted electronic devices (e.g., pacemaker)
  • Prior head trauma
  • Pregnant
  • IQ \< 80
  • Taking cholinesterase inhibitory, memantine, or psychotropic medication
  • Taking anti-depressants or anti-anxiety medication
  • Color blind
  • Substance abuse
  • Glaucoma
  • Macular degeneration
  • Amblyopia (lazy eye)
  • Strabismus (crossed eyes)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94158, United States

Location

MeSH Terms

Conditions

Cognitive Dysfunction

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Results Point of Contact

Title
Dr. Theodore Zanto
Organization
University of California San Francisco

Study Officials

  • Theodore Zanto, Ph.D.

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 10, 2020

First Posted

November 30, 2020

Study Start

January 11, 2021

Primary Completion

December 31, 2021

Study Completion

May 31, 2022

Last Updated

May 11, 2023

Results First Posted

May 11, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will share

The dataset includes self-reported information, behavioral and electrophysiological data. The final dataset will be stripped of identifiers prior to release for sharing, thereby anonymizing the data. We will make the anonymized data available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to attempt to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed. This will be in accordance with human subject regulations.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
The data will be available after the results have been determined and the study researchers are unblinded. The data will be available indefinitely upon request.
Access Criteria
Contact PI.

Locations